<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/6615</identifier>
				<datestamp>2020-08-21T22:23:21Z</datestamp>
				<setSpec>aabp:RD</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">AT-4526, A New Quinolone Derivative:  Its Pharmacokinetics in Cats, Dogs, Pigs, and Calves</dc:title>
	<dc:creator xml:lang="en">Kouno, Kaoru</dc:creator>
	<dc:creator xml:lang="en">Sakaguchi, Yuzo</dc:creator>
	<dc:creator xml:lang="en">Nakai, Masahiro</dc:creator>
	<dc:creator xml:lang="en">Yoshida, Motonobu</dc:creator>
	<dc:creator xml:lang="en">Matsumoto, Shuji</dc:creator>
	<dc:creator xml:lang="en">Kawamura, Tadashi</dc:creator>
	<dc:creator xml:lang="en">Hatano, Naonobu</dc:creator>
	<dc:creator xml:lang="en">Katae, Hiromi</dc:creator>
	<dc:creator xml:lang="en">Hattori, Hiroaki</dc:creator>
	<dc:creator xml:lang="en">Nakamura, Shinichi</dc:creator>
	<dc:subject xml:lang="en">quinolone derivative</dc:subject>
	<dc:subject xml:lang="en">antibacterial</dc:subject>
	<dc:subject xml:lang="en">Mycoplasma spp</dc:subject>
	<dc:subject xml:lang="en">gram-positive</dc:subject>
	<dc:subject xml:lang="en">gram-negative</dc:subject>
	<dc:subject xml:lang="en">pharmacokinetics</dc:subject>
	<dc:subject xml:lang="en">AT-4526</dc:subject>
	<dc:subject xml:lang="en">cats</dc:subject>
	<dc:subject xml:lang="en">dogs</dc:subject>
	<dc:subject xml:lang="en">pigs</dc:subject>
	<dc:subject xml:lang="en">calves</dc:subject>
	<dc:description xml:lang="en">AT-4526, 1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid, a new quinolone derivative, is under development as veterinary medicine. It has broad and potent antibacterial activities against gram-positive and gram-negative bacteria, anaerobes and Mycoplasma spp. (1). Its in vivo activity was generally higher than those of structurally related enrofloxacin and certain antibiotics such as oxytetracycline, kanamycin, and ampicillin in experimental infections in mice even in the case of less potent in vitro activity (1).
This paper describes the pharmacokinetics of AT-4526 in cats, dogs, pigs and calves.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>1992-08-31</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/aabp/article/view/6615</dc:identifier>
	<dc:identifier>10.21423/aabppro19926615</dc:identifier>
	<dc:source xml:lang="en">American Association of Bovine Practitioners  Conference Proceedings; 1992: Volume 3; 178-184</dc:source>
	<dc:source>1079-9737</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/aabp/article/view/6615/7176</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 1992 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
